세계의 말라리아 진단 시장 규모, 점유율 및 동향 분석 보고서 : 기술별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Malaria Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microscopy, Rapid Diagnostic Tests), By End Use (Clinics, Hospitals), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,350,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,753,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,560,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

말라리아 진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 말라리아 진단 시장 규모는 2024년부터 2030년까지 2.6%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 9억 50만 달러에 달할 것으로 예상됩니다.

열대성 질환이 유행하는 국가들에서 열대성 질환 증가, 새로운 진단 기술 시장 개척, 지역 정부 및 민간 투자자들의 투자 증가가 시장 성장을 가속할 것으로 예상됩니다. 말라리아는 기후 변화, 낮은 경제 성장, 미개발된 의료 인프라, 고급 치료 접근성 부족 등의 이유로 열대 및 아열대 지역에서 흔히 발생하는 가장 널리 퍼져 있는 생명을 위협하는 질병 중 하나입니다.

정부 이니셔티브와 시장 진출기업의 투자 증가는 가까운 시일 내에 시장 성장을 가속할 것으로 예상되며, 코로나19 팬데믹 기간 동안 아프리카에서 풍부하게 제공되는 항말라리아 치료 옵션은 감염 확산을 관리하고 통제하는 데 사용되었으며, 코로나19 바이러스 와 더불어 말라리아 환자가 계속 증가함에 따라 코로나19 팬데믹 기간 동안 시장은 크게 성장했습니다.

이 질병의 전염을 억제하기 위해 많은 대기업들이 말라리아 퇴치 프로그램을 시행하고 있습니다. 예를 들어, 노바티스의 말라리아 이니셔티브는 말라리아 퇴치와 통제를 촉진하는 것을 목표로 하고 있습니다. 노바티스는 다양한 조직과 함께 60개국에서 7억 5,000만 명에게 비영리 치료제를 제공했습니다. 이러한 이니셔티브는 새로운 기술 개발을 촉진하고 시장 침투를 촉진하는 데 도움이 될 것으로 기대됩니다.

말라리아 진단 시장 보고서 하이라이트

• 현미경 검사는 전통적으로 말라리아 원충을 검출하는 데 사용되어 왔으며, 현미경 검사 기술 분야를 주도하고 있습니다.
• RDT는 사용의 용이성, 편의성, 빠른 진단으로 인해 가장 큰 매출 점유율을 차지할 것으로 예상됩니다.
• 분자진단 검사 분야는 정확성과 낮은 기생충 수 검출 능력으로 인해 예측 기간 동안 가장 빠르게 성장하는 기술 분야가 될 것으로 예상됩니다.
• 아프리카는 높은 발병률과 다양한 말라리아 진단 기술의 채택 증가로 인해 2023년 시장을 주도했습니다.
• 동남아시아는 말라리아의 재발이 잦고, 말라리아 발병을 억제하기 위한 노력으로 인해 CAGR 2.3%로 성장할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 말라리아 진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 말라리아 진단 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 말라리아 진단 시장 : 기술 추정·동향 분석

• 기술 시장 점유율, 2023년·2030년
• 부문 대시보드
• 세계의 말라리아 진단 시장 : 기술 전망 별
• 시장 규모와 예측과 동향 분석, 2018년-2030년

제5장 말라리아 진단 시장 : 최종 용도 추정·동향 분석

• 메소드 시장 점유율, 2023년·2030년
• 부문 대시보드
• 세계의 말라리아 진단 시장 전망 : 최종 용도별
• 시장 규모와 예측과 동향 분석, 2018년-2030년

제6장 말라리아 진단 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년·2030년
• 지역 시장 대시보드
• 세계의 지역 시장 스냅숏
• 시장 규모, 예측 동향 분석, 2018년-2030년 :
• 아프리카
  • 나이지리아
  • 콩고 민주공화국
  • 탄자니아 연합 공화국
  • 우간다
  • 남아프리카공화국
  • 모잠비크
  • 앙골라
  • 가나
  • 보츠와나
  • 나미비아
• 동남아시아
  • 인도
  • 미얀마
  • 인도네시아
• 동 지중해
  • 사우디아라비아
  • 파키스탄
• 서태평양
  • 중국
  • 파푸아뉴기니
  • 캄보디아
• 아메리카
  • 베네수엘라
  • 브라질
  • 콜롬비아
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 터키

제7장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁 분류
• 벤더 구도
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Access Bio, Inc.
  • Abbott Laboratories
  • Premier Medical Corporation Pvt. Ltd.
  • Sysmex Partec GmbH
  • Siemens Healthineers
  • bioMerieux
  • Beckman Coulter, Inc.
  • Leica Microsystems GmbH
  • Bio-Rad Laboratories, Inc.

LSH

영문 목차

영문목차

Malaria Diagnostics Market Growth & Trends:

The global malaria diagnostics market size is projected to reach USD 900.5 million by 2030, expanding at a CAGR of 2.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the tropical disease in endemic countries, development of novel diagnostic techniques, and rising investments by regional governments and private investors are expected to propel market growth. Malaria is one of the most widespread life-threatening diseases, commonly occurring in the tropical and subtropical regions due to changing climate, low economic growth, underdeveloped healthcare infrastructure, and lack of access to advanced treatment.

Increasing number of government initiatives and investments by market participants are also anticipated to fuel market growth in the near future. Use of antimalarial treatments options that were abundantly available in the African region were used for the management and control of spread during the COVID-19 pandemic. The market noticed a significant boost during the COVID-19 outbreak owing to the ever-increasing malaria cases in addition to the COVID-19 virus.

A large number of malarial elimination programs are being undertaken by major companies to reduce the disease prevalence. For instance, Novartis's Malaria Initiative was aimed at facilitating malaria elimination and control. Along with various organizations, the company has provided non-profit treatment to 750 million people across 60 countries. Thus, such initiatives are anticipated to facilitate the development of novel technologies and aid in market penetration.

Malaria Diagnostics Market Report Highlights:

• Conventional usage of microscopic examination for detection of malarial parasite has driven the microscopy technology segment
• RDTs are anticipated to account for the largest revenue share owing to ease of usage, convenience, and rapid diagnosis.
• The molecular diagnostic tests segment is projected to be the fastest-growing technology segment during the forecast period owing to their accuracy and capability of detecting low parasite count.
• Africa led the market in 2023 due to high disease incidence and increased adoption of various malarial diagnostic techniques in the region.
• Southeast Asia is expected to grow at a CAGR of 2.3% owing to high disease reoccurrence and initiatives undertaken to curb malarial incidence.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Malaria Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing demand for diagnostic tools in malaria-endemic countries
    • 3.2.1.2. Development of technologically advanced and efficient diagnostics
    • 3.2.1.3. Market players and private investors to curb the prevalence of malaria
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Increasing number of countries in the malaria elimination phase
    • 3.2.2.2. Demand for low-cost malaria diagnostic tests
• 3.3. Malaria Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Malaria Diagnostics Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Malaria Diagnostics Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Molecular Diagnostic Tests
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Conventional PCR
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Modernized PCR
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Microscopy
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Rapid Diagnostic Tests (RDT)

Chapter 5. Malaria Diagnostics Market: End Use Estimates & Trend Analysis

• 5.1. Method Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Malaria Diagnostics Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hospitals & Clinics
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.4.2. Diagnostic Centers
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Academic and Research Institutes
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Malaria Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. Africa
  • 6.5.1. Nigeria
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Nigeria market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Democratic Republic of the Congo
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Democratic Republic of the Congo market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. United Republic of Tanzania
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. United Republic of Tanzania market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Uganda
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Uganda market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Africa
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Mozambique
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Mozambique market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Angola
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Angola market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Ghana
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Ghana market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.9. Botswana
    • 6.5.9.1. Key country dynamics
    • 6.5.9.2. Regulatory framework/ reimbursement structure
    • 6.5.9.3. Competitive scenario
    • 6.5.9.4. Botswana market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.10. Namibia
    • 6.5.10.1. Key country dynamics
    • 6.5.10.2. Regulatory framework/ reimbursement structure
    • 6.5.10.3. Competitive scenario
    • 6.5.10.4. Namibia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. South East Asia
  • 6.6.1. India
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Myanmar
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Myanmar market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Indonesia
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Indonesia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Eastern Mediterranean
  • 6.7.1. Saudi Arabia
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Pakistan
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Pakistan market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Western Pacific
  • 6.8.1. China
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Papua New Guinea
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Papua New Guinea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Cambodia
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Cambodia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Americas
  • 6.9.1. Venezuela
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. Venezuela market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. Colombia
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Colombia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Europe
  • 6.10.1. UK
    • 6.10.1.1. Key country dynamics
    • 6.10.1.2. Regulatory framework/ reimbursement structure
    • 6.10.1.3. Competitive scenario
    • 6.10.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10.2. Germany
    • 6.10.2.1. Key country dynamics
    • 6.10.2.2. Regulatory framework/ reimbursement structure
    • 6.10.2.3. Competitive scenario
    • 6.10.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10.3. France
    • 6.10.3.1. Key country dynamics
    • 6.10.3.2. Regulatory framework/ reimbursement structure
    • 6.10.3.3. Competitive scenario
    • 6.10.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10.4. Turkey
    • 6.10.4.1. Key country dynamics
    • 6.10.4.2. Regulatory framework/ reimbursement structure
    • 6.10.4.3. Competitive scenario
    • 6.10.4.4. Turkey market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Access Bio, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Abbott Laboratories
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Premier Medical Corporation Pvt. Ltd.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Sysmex Partec GmbH
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Siemens Healthineers
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. bioMerieux
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Beckman Coulter, Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Leica Microsystems GmbH
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Bio-Rad Laboratories, Inc.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives

관련자료